This increase in septal flow was immediately abrogated upon stopping CRT, suggesting that CRT alleviates impediment of perfusion by the abnormal contraction pattern [ 25].
Thielmann et al [17] have demonstrated that CRT residue Trp183 plays a critical role in GABARAP-CRT interaction.
In Asia, a Japanese phase I study indicated that CRT might cause surgery to be delayed, but showed promise for resectable advanced gastric cancer, while a Korean phase I study showed that CRT could be explored more extensively [ 36].
Ecto-CRT correlated with the presence of phosphorylated eIF2 α within the blasts, in line with the possibility that CRT exposure results from an endoplasmic reticulum stress response.
Finally, we found that CRT had a markedly beneficial histological effect on gastric cancer.
We hypothesized that CRT with triple-site ventricular stimulation (TRIV) may improve resynchronization and its outcomes.
It is suggested that CRT is a possible second-line therapy for advanced or recurrent gastric cancer.
We suggest that CRT with S-1 be chosen as the first-line therapy for SCC of the rectum.
The results suggested that CRT with S-1 was chosen as the first-line therapy for SCC of the rectum; although, surgery might be an effective salvage therapy.
Recently, some studies have reported that CRT might also be effective in the treatment of primary SCC of the rectum [4-9].
Results showed that CRT produced an overall improvement on neurocognition (Mean effect size = 0.5), particularly in verbal and nonverbal memory, and executive function.
